Key result
Thrombocytopenia after TAVR is common, reaching 50-60% below baseline, and while adverse sequelae are rare, persistent thrombocytopenia is associated with increased mortality.
Answers are grounded in this paper and cite their sources.
Persistent thrombocytopenia after TAVR is associated with increased mortality, suggesting it could be a marker for patients who derive limited benefit from the procedure.
Key Points Thrombocytopenia after transcatheter aortic valve replacement (TAVR) is common and usually reaches 50–60% below baseline platelet levels. Adverse sequelae are rare but persistent thrombocytopenia is associated with increased mortality. Further studies identifying patients with comorbidities that lead to persistent thrombocytopenia and higher mortality might help identify patients with limited benefit from TAVR.
No takes yet. Share an insight, caveat, or question.
Peter C. Block (2014) conducted an editorial in Thrombocytopenia after transcatheter aortic valve replacement (TAVR). Transcatheter aortic valve replacement (TAVR) was evaluated. Thrombocytopenia after TAVR is common, reaching 50-60% below baseline, and while adverse sequelae are rare, persistent thrombocytopenia is associated with increased mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: